Aggarwal et al. (2019) demonstrated that PI3K inhibitors, such as PI-103, PI828, and PX-866, appear promising for the treatment of oral cancer, exhibiting anti-tumor activity by inhibiting inflammation, blocking the cell cycle, suppressing angiogenesis, and enhancing apoptosis [52]. Here, PIK3CA is linked to lip and oral cavity carcinoma.